Rethinking Selectivity: Mixed-Mode Chromatography Across the Bioprocessing Landscape
As bioprocessing evolves, downstream separation strategies must keep pace. This two-part series explores how mixed-mode chromatography can offer new dimensions of selectivity across diverse therapeutic modalities, from antibodies to mRNA, through practical examples that illustrate its role in downstream process development.
November 17
10:00 AM EST
Virtual
Agenda
Tuesday
10:00 AM EST
Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges
Discover how a next-generation mixed-mode weak anion exchange resin can expand polishing options for challenging biologics. Learn how adjustable charge functionality enabled improved impurity removal, higher product yields, and greater process flexibility across diverse antibody formats.
Speaker: Michael Rauscher, MS
Exploring the Use of Multimodal Chromatography for the Purification of mRNA Vaccines
Discover how a next-generation mixed-mode weak anion exchange resin can expand polishing options for challenging biologics. Learn how adjustable charge functionality enabled improved impurity removal, higher product yields, and greater process flexibility across diverse antibody formats.
Speaker: Sara Sousa Rosa
Speakers
Michael Rauscher, MS
Associate Principal Scientist, Downstream Process Development and Engineering, Merck & Co., Inc.
Sara Sousa Rosa, PhD
Research Fellow, UCL Biochemical Engineering